Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,001 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial.
Adamson D, Byrne A, Porter C, Blazeby J, Griffiths G, Nelson A, Sewell B, Jones M, Svobodova M, Fitzsimmons D, Nixon L, Fitzgibbon J, Thomas S, Millin A, Crosby T, Staffurth J, Hurt C. Adamson D, et al. Among authors: porter c. Lancet Gastroenterol Hepatol. 2021 Apr;6(4):292-303. doi: 10.1016/S2468-1253(21)00004-2. Epub 2021 Feb 19. Lancet Gastroenterol Hepatol. 2021. PMID: 33610215 Free PMC article. Clinical Trial.
Palliative radiotherapy combined with stent insertion to reduce recurrent dysphagia in oesophageal cancer patients: the ROCS RCT.
Adamson D, Blazeby J, Porter C, Hurt C, Griffiths G, Nelson A, Sewell B, Jones M, Svobodova M, Fitzsimmons D, Nixon L, Fitzgibbon J, Thomas S, Millin A, Crosby T, Staffurth J, Byrne A. Adamson D, et al. Among authors: porter c. Health Technol Assess. 2021 May;25(31):1-144. doi: 10.3310/hta25310. Health Technol Assess. 2021. PMID: 34042566 Free PMC article. Clinical Trial.
The VALTIVE1 study protocol: a study for the validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitors.
Carucci M, Clamp A, Zhou C, Hurt C, Glasspool R, Monaghan PJ, Thirkettle S, Wheatley M, Mahmood M, Narasimham M, Cox T, Morrison H, Campbell S, Nelson A, Holland-Hart D, Hopewell-Kelly N, Thomas A, Porter C, Slusarczyk M, Irving A, Dive C, Adams R, Jayson GC. Carucci M, et al. Among authors: porter c. BMC Cancer. 2024 Oct 24;24(1):1309. doi: 10.1186/s12885-024-13073-0. BMC Cancer. 2024. PMID: 39448911 Free PMC article.
Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial.
Murphy AD, Porter C, White A, Irving A, Adams R, Ray R, Casbard A, Mahmood RD, Karanth S, Zhou C, Pugh J, Wheeler C, Roberts V, Arnetoli G, Salih Z, Hasan J, Mitchell C, Morgan RD, Clamp AR, Jayson GC. Murphy AD, et al. Among authors: porter c. Int J Gynecol Cancer. 2024 Jul 1;34(7):1034-1040. doi: 10.1136/ijgc-2024-005455. Int J Gynecol Cancer. 2024. PMID: 38724236 Clinical Trial.
Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial.
Fennell DA, Porter C, Lester J, Danson S, Blackhall F, Nicolson M, Nixon L, Gardner G, White A, Griffiths G, Casbard A. Fennell DA, et al. Among authors: porter c. EClinicalMedicine. 2022 Aug 11;52:101595. doi: 10.1016/j.eclinm.2022.101595. eCollection 2022 Oct. EClinicalMedicine. 2022. PMID: 35990583 Free PMC article.
Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial.
Fennell DA, Porter C, Lester J, Danson S, Taylor P, Sheaff M, Rudd RM, Gaba A, Busacca S, Nixon L, Gardner G, Darlison L, Poile C, Richards C, Jordan PW, Griffiths G, Casbard A. Fennell DA, et al. Among authors: porter c. EClinicalMedicine. 2022 May 19;48:101432. doi: 10.1016/j.eclinm.2022.101432. eCollection 2022 Jun. EClinicalMedicine. 2022. PMID: 35706488 Free PMC article.
Risk reduction in SARS-CoV-2 infection and reinfection conferred by humoral antibody levels among essential workers during Omicron predominance.
Hollister J, Porter C, Sprissler R, Beitel SC, Romine JK, Uhrlaub JL, Grant L, Yoo YM, Fowlkes A, Britton A, Olsho LEW, Newes-Adeyi G, Fuller S, Zheng PQ, Gaglani M, Rose S, Dunnigan K, Naleway AL, Gwynn L, Caban-Martinez A, Schaefer Solle N, Tyner HL, Philips AL, Hegmann KT, Yoon S, Lutrick K, Burgess JL, Ellingson KD. Hollister J, et al. Among authors: porter c. PLoS One. 2024 Dec 31;19(12):e0306953. doi: 10.1371/journal.pone.0306953. eCollection 2024. PLoS One. 2024. PMID: 39739951 Free PMC article.
Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity.
Morita D, Rosewell Shaw A, Biegert G, Porter C, Woods M, Vasileiou S, Lim B, Suzuki M. Morita D, et al. Among authors: porter c. J Immunother Cancer. 2024 Dec 9;12(12):e009741. doi: 10.1136/jitc-2024-009741. J Immunother Cancer. 2024. PMID: 39653552 Free PMC article.
2,001 results